Lv41
534 积分 2022-08-22 加入
Ponatinib in CML and Ph+ ALL: balancing high efficacy with vascular safety
21天前
已完结
Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke
22天前
已完结
Old problems, new tools: ZR2 in older patients with DLBCL
24天前
已完结
Immunochemotherapy plus radiotherapy versus immunochemotherapy alone as first-line treatment for treatment-naïve, advanced esophageal squamous cell carcinoma (AEC-ICR-1st): A multi-center cohort study
2个月前
已完结
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study
2个月前
已完结
Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma
2个月前
已完结
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
2个月前
已完结
Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma
2个月前
已完结
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
2个月前
已完结
Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases
2个月前
已完结